


PHARMACEUTICAL 2022

Nuvation Bio Inc. Rank 56 of 475





PHARMACEUTICAL 2022



Nuvation Bio Inc. Rank 56 of 475

The relative strengths and weaknesses of Nuvation Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvation Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 186% points. The greatest weakness of Nuvation Bio Inc. is the variable Revenues, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 391% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	772,073
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,925
Liabilities, Non-Current	2,192
Other Assets	3,292
Other Compr. Net Income	-2,742
Other Expenses	0
Other Liabilities	11,037
Other Net Income	6,470
Property and Equipment	786
Research and Development	69,037
Revenues	0
Selling, General and Administrative Expense	24,281

Output Variable	Value in 1000 USD
Assets	776,151
Liabilities	30,154
Expenses	93,318
Stockholders Equity	745,997
Net Income	-86,848
Comprehensive Net Income	-88,219
Economic Capital Ratio	115%